EXEL: Exelixis Inc Price-to-Revenue Multiple

Symbol and logo of brand Exelixis Inc (EXEL)

Steady demand for Cabometyx generates a reliable cash flow, supporting the historical P/S ratio for Exelixis, Inc. (EXEL). The 6.90 metric confirms the current valuation level. Financial independence from debt is based on revenues from the flagship drug, while the integration of ESG standards ensures the ethics of research and the environmental safety of drug production.

EXEL Exelixis Inc. Market Cap to Revenue (07/04/2022 - 11/13/2026)

Analytical breakdowns for Exelixis Corp (EXEL)

- share price and consensus valuation forecast:
Price Performance Chart exelixis.com|EXEL - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Exelixis Corp|EXEL - Enterprise Value
- book capitalization data:
Net Asset Value per Share Exelixis|EXEL - Company Net Assets|Market Cap to Book Value Multiple exelixis.com|EXEL - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Exelixis, Inc.|EXEL - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Exelixis Inc.|EXEL - Company Total Debt|Debt to Net Assets Ratio Exelixis Corp|EXEL - Company Long-Term Liabilities|Amount of Current Liabilities Exelixis|Intermediate Coverage Ratio exelixis.com
- earnings and multiples data:
EXEL - Net Profit|Expected Net Profit Exelixis, Inc.|EXEL - Price to Earnings Ratio|Future Price to Earnings Multiple Exelixis Inc|EXEL - PEG Multiple|EV/EBITDA Multiple Exelixis Corp|EXEL - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Exelixis|EXEL - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months exelixis.com|EXEL - Earnings growth in current year|Expected net earnings per share growth next year Exelixis, Inc.
- sales revenue and business income indicators:
EXEL - Company Sales|Company Revenue Forecast exelixis.com|EXEL - P/S Multiple|Market Cap to Future Revenue Ratio Exelixis Corp
Summary company analytics:exelixis.com, EXEL
Mass-produced product of exelixis.com

The ratio of market capitalization to annual sales determines the value of each dollar of revenue, allowing for an assessment of whether market pricing is fair under tight monetary policy. For Exelixis, Inc. (EXEL), which depends on a single drug, the revenue multiple trend serves as an indicator of investor sensitivity to patent risks and clinical trial results, helping to distinguish fundamental undervaluation from business stagnation.

Who Exelixis, Inc. competes with

GMAB (genmab.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple NUVL (Nuvalent)|Price-to-Revenue Multiple Kymera Therapeutics, Inc.|IDEAYA Bio - P/S Multiple|Price to Sales Enliven Corp|ORIC (ORIC Pharmaceuticals) - Market Cap to Revenue|RLAY: Market Cap to Sales Volume|NRIX (Nurix Therapeutics, Inc.) - P/S Multiple|Price to Sales Tyra Biosciences Inc TYRA|P/S Multiple VSTM|Monte Rosa Corp - Market Cap to Revenue Ratio|Cullinan Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMRX|CCCC: Market Cap to Revenue|Black Diamond Therapeutics, Inc. - Market Cap to Sales Volume|RPTX: P/S Multiple|PMV Pharmaceuticals, Inc - Market Capitalization-to-Revenue Ratio|KPTI (Karyopharm Therapeutics, Inc.) - P/S Multiple|Price to Sales Propanc Biopharma, Inc. PPCB|Price-to-Revenue Ratio Bio Green Med Solution (BGMS)|AADI (aadibio.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALRN (Aileron Therapeutics, Inc.)|P/S Multiple Blueprint Medicines Corp. BPMC|GLYC - Price-to-Revenue Ratio|Price-to-Sales Ratio SWTX